Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 7/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837250 | 0.90 | KCNH2 (0.42) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL310842 | 0.89 | KCNH2 (0.49) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2835400 | 0.83 | KCNH2 (0.50) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2836104 | 0.83 | KCNH2 (0.50) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2837215 | 0.82 | KCNH2 (0.48) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2834508 | 0.82 | KCNH2 (0.48) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL483745 | 0.80 | BTK (0.40) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2832497 | 0.79 | KCNH2 (0.59) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2832873 | 0.79 | KCNH2 (0.59) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL2837151 | 0.78 | KCNH2 (0.55) | KCNH2SCN3ASCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20100113521-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| EP-2129381-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | Glaxo Group Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| EP-2117538-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| EP-2117562-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
| WO-2008090117-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090114-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090115-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| EP-1934176-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042240-A1 | QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | KCNJ2, SCN5A, GRIK5 | KCNH2 7/4885SCN3A 63/4885SCN1A 48/4885 |
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | KCNH2 3260/4885SCN3A 2696/4885SCN1A 1086/4885 |
| US-20100113521-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5-(5-TRIFLUOROMETHYL-TETRAZOL-1-YL-BENZYL)-(2S-PHENYLPIPERIDIN-3S-YL-) | KCNJ2, TRPV1, SCN5A | KCNH2 11/4885SCN3A 40/4885SCN1A 19/4885 |
| US-20090326032-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | TACR2, TACR1, KCNH3 | KCNH2 5/4885SCN3A 35/4885SCN1A 17/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | KCNH2 15/4885SCN3A 11/4885SCN1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.